BRM 421
Alternative Names: BRM 421; GPN 00136; PDSPLatest Information Update: 26 Feb 2026
At a glance
- Originator MacKay Memorial Hospital
- Developer BRIM Biotechnology
- Class Peptides
- Mechanism of Action Cell proliferation stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Dry eyes
- Clinical Phase Unknown Limbal stem cell deficiency
- Preclinical Osteoarthritis
- No development reported Alopecia; Corneal injuries
Most Recent Events
- 20 Feb 2026 Clinical trial in Limbal stem cell deficiency in USA (Ophthalmic) (NCT07422389)
- 24 Jul 2025 BRIM Biotechnology plans phase II trial in Dry Eyes in Taiwan in November 2025 (NCT07078955)
- 04 Dec 2024 BRIM Biotechnology plans a phase I trial for Osteoarthritis (Intra-articular, Injection) in 2025 (BRIM Biotechnology pipeline, December 2024)